Atacicept in Subjects With IgA Nephropathy
← catalyst calendarSponsored by Vera Therapeutics, Inc. (industry) · VERA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
376estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-29 | actual | When the study began enrolling |
| Primary completion | 2025-05-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2021-01-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- IgA Nephropathy
- Berger Disease
Interventions
- Biological: Atacicept — also filed as VT-001
- Other: Placebo to match Atacicept
Primary outcome
what the primary-completion date above is the date OFChange from baseline in urine protein to creatinine ratio (UPCR)
measured 36 Weeks
Publications
- PMID 41620980 — linked by the registry
- PMID 41196369 — linked by the registry
- PMID 39462308 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · VERA's whole pipeline · Catalyst calendar · Every registered study · What changed